1)Averbuch D, Cordonnier C, Livermore DM, et al:Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 98:1836-1847,2013
2)Magiorakos AP, Srinivasan A, Carey RB, et al:Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281,2012
3)Freifeld AG, Bow EJ, Sepkowitz KA, et al:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56-e93,2011
4)Satlin MJ, Walsh TJ:Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis 19:e12762,2017
5)Chuang YC, Lin HY, Chen PY, et al:Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis 64:1026-1034,2017
6)Iwata K:Are all fosfomycins alike? J Infect Chemother 22:724,2016
7)Satlin MJ, Jenkins SG, Walsh TJ:The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 58:1274-1283,2014